Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the.
18.10.2022 - EscharEx’s promising results from the completed Phase 2 trials were highlightedYAVNE, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic . Seite 1